Latest News

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • How does the human brain tackle problems it did not evolve to solve?

  • Patient perceptions of physician compassion measured

  • Reviving drugs with anti-stroke potential, minus side effects

  • Intimate partners with low self-esteem stay in unhappy relationships

  • New compounds protect nervous system from the structural damage characteristic of multiple sclerosis

  • Shake it off? Not so easy for people with depression, new brain research suggests

  • Introverts prefer mountains

  • Research of plain wren duets could help further understand fundamentals of conversation

  • Protein pathway involved in brain tumor stem cell growth identified

  • Altering perception of feeding state may promote healthy aging

  •